scholarly journals Survival benefit of definitive therapy in patients with clinically advanced prostate cancer: estimations of the number needed to treat based on competing-risks analysis

2014 ◽  
Vol 114 (6b) ◽  
pp. E62-E69 ◽  
Author(s):  
Giorgio Gandaglia ◽  
Maxine Sun ◽  
Quoc-Dien Trinh ◽  
Andreas Becker ◽  
Jonas Schiffmann ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Competing Risks ◽  
Survival Benefit ◽  
Advanced Prostate Cancer ◽  
Number Needed To Treat ◽  
Competing Risks Analysis ◽  
Definitive Therapy

A Competing-Risks Analysis of Survival After Alternative Treatment Modalities for Prostate Cancer Patients: 1988–2006

2011 ◽  
Vol 59 (1) ◽  
pp. 88-95 ◽  
Author(s):  
Firas Abdollah ◽  
Maxine Sun ◽  
Rodolphe Thuret ◽  
Claudio Jeldres ◽  
Zhe Tian ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Patients ◽  
Competing Risks ◽  
Alternative Treatment ◽  
Treatment Modalities ◽  
Competing Risks Analysis

1015 Cardiovascular disease and prostate cancer: A competing-risks analysis

2013 ◽  
Vol 12 (1) ◽  
pp. e1015
Author(s):  
J. Hansen ◽  
F.K. Chun ◽  
M. Rink ◽  
S.F. Shariat ◽  
M. Graefen ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cardiovascular Disease ◽  
Competing Risks ◽  
Competing Risks Analysis

1488 CARDIOVASCULAR DISEASE AND PROSTATE CANCER: A COMPETING-RISKS ANALYSIS

2013 ◽  
Vol 189 (4S) ◽  
Author(s):  
Jens Hansen ◽  
Marco Bianchi ◽  
Felix K-H Chun ◽  
Andreas Becker ◽  
Michael Rink ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cardiovascular Disease ◽  
Competing Risks ◽  
Competing Risks Analysis

Docetaxel Plus Prednisone or Mitoxantrone Plus Prednisone for Advanced Prostate Cancer: Updated Survival in the TAX 327 Study

2008 ◽  
Vol 26 (2) ◽  
pp. 242-245 ◽  
Author(s):  
Dominik R. Berthold ◽  
Gregory R. Pond ◽  
Freidele Soban ◽  
Ronald de Wit ◽  
Mario Eisenberger ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Survival Benefit ◽  
Advanced Prostate Cancer ◽  
Specific Antigen ◽  
Weekly Docetaxel ◽  
Original Analysis ◽  
Hormone Resistant Prostate Cancer ◽  
Baseline Psa

Purpose The TAX 327 study compared docetaxel administered every 3 weeks (D3), weekly docetaxel (D1), and mitoxantrone (M), each with prednisone (P), in 1,006 men with metastatic hormone-resistant prostate cancer (HRPC). The original analysis, undertaken in August 2003 when 557 deaths had occurred, showed significantly better survival and response rates for pain, prostate-specific antigen (PSA), and quality of life for D3P when compared with MP. Here, we report an updated analysis of survival. Methods Investigators were asked to provide the date of death or last follow-up for all participants who were alive in August 2003. Results By March 2007, data on 310 additional deaths were obtained (total = 867 deaths). The survival benefit of D3P compared with MP has persisted with extended follow-up (P = .004). Median survival time was 19.2 months (95% CI, 17.5 to 21.3 months) in the D3P arm, 17.8 months (95% CI, 16.2 to 19.2 months) in the D1P arm, and 16.3 months (95% CI, 14.3 to 17.9 months) in the MP arm. More patients survived ≥ 3 years in the D3P and D1P arms (18.6% and 16.6%, respectively) compared with the MP arm (13.5%). Similar trends in survival between treatment arms were seen for men greater than and less than 65 years of age, for those with and without pain at baseline, and for those with baseline PSA greater than and less than the median value of 115 ng/mL. Conclusion The present analysis confirms that survival of men with metastatic HRPC is significantly longer after treatment with D3P than with MP. Consistent results are observed across subgroups of patients.

Sign in / Sign up

Export Citation Format

Share Document